Although there has been an intense interest in the care of the adult with congenital heart disease (ACHD), these guidelines are usually not focused on the concepts of immediate postoperative care. The 2 most common perioperative complications are heart failure and atrial dysrhythmias. The broad etiological categories for ACHD and heart failure include primary pump failure (systolic dysfunction) and hypertrophy (diastolic dysfunction) of the right, left, or single ventricle. Some conditions with a pressure-loaded systemic right ventricle as well as patients with a functionally single ventricle may be particularly prone to develop heart failure; in others, right heart failure may occur in patients with Ebstein anomaly or with tetralogy of Fallot after corrective repair but with varying degrees of pulmonary insufficiency, and left heart failure can be a result of mitral or aortic insufficiency. The management of postoperative atrial tachycardia in the ACHD patient actually begins prior to surgery. Assessment of arrhythmia history, complete determination of risk, inducibility and arrhythmia substrate, preoperative planning of pacing sites, and optimal pacing strategies all assist to bring about optimal postoperative outcomes. Ideal perioperative care of the ACHD involves a multidisciplinary team of pediatric and adult cardiologists, pediatric and adult intensivists, cardiac surgeons, and nursing staff along with a myriad of adult subspecialists such as pulmonology, nephrology, endocrinology, and others including psychiatry.
WebbCLJenkinsKJKarpawichPP. Collaborative care for adults with congenital heart disease. Circulation. 2002;105:2318.
2.
DearaniJAMavroudisCQuintessenzaJA. Surgical advances in the treatment of adults with congenital heart disease. Curr Opin Pediatr. 2009;21(5):565–572.
3.
DearaniJAConnollyHMMartinezR. Caring for adults with congenital heart disease: Successes and challenges for 2007 and beyond. In: AndersonRHJacobsJPWernovskyG, eds. 2007 supplement to Cardiology in the Young: Annual Heart Week in Florida supplement number 5—Controversies and challenges facing pediatric cardiovascular practitioners and their patients. Cardiol Young. 2007;17(suppl 2):87–96.
4.
RossanoJWSmithEOFraserCD. Adults undergoing cardiac surgery at a children’s hospital: an analysis of perioperative morbidity. Ann Thorac Surg. 2007;83(2):606–612.
5.
PiranSVeldtmanGSiuSWebbGDLiuPP.Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation. 2002;105(10):1189–1194.
6.
McKeePACastelliWPMcNamaraPMKannelWB.The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441–1446.
7.
HornungTSBernardEJJaeggiETHowman-GilesRBCelermajerDSHawkerRE.Myocardial perfusion defects and associated systemic ventricular dysfunction in congenitally corrected transposition of the great arteries. Heart. 1998;80(4):322–326.
8.
HornungTSBernardEJCelermajerDS. Right ventricular dysfunction in congenitally corrected transposition of the great arteries. Am J Cardiol. 1999;84(9):1116–1119, A10.
9.
GrahamTPJrBernardYDMellenBG. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36(1):255–261.
10.
PresbiteroPSomervilleJRabajoliFStoneSConteMR.Corrected transposition of the great arteries without associated defects in adult patients: clinical profile and follow up. Br Heart J. 1995;74(1):57–59.
11.
ImamuraMDrummond-WebbJJMurphyDJJr. Results of the double switch operation in the current era. Ann Thorac Surg. 2000;70(1):100–105.
12.
GrahamTPJr.Hemodynamic residua and sequelae following intraatrial repair of transposition of the great arteries: a review. Pediatr Cardiol. 1982;2(3):203–213.
13.
GrahamTPJrBurgerJBenderHWHammonJWBoucekRJJrAppletonS.Improved right ventricular function after intra-atrial repair of transposition of the great arteries. Circulation. 1985;72(3 pt 2):II45–II51.
14.
WongKYVenablesAWKellyMJKalffV.Longitudinal study of ventricular function after the Mustard operation for transposition of the great arteries: a long term follow up. Br Heart J. 1988;60(4):316–323.
15.
ReichOVoriskovaMRuthC. Long-term ventricular performance after intra-atrial correction of transposition: left ventricular filling is the major limitation. Heart. 1997; 78(4):376–381.
16.
SantamoreWPDell’ItaliaLJ.Ventricular interdependence: significant left ventricular contributions to right ventricular systolic function. Prog Cardiovasc Dis. 1998;40(4):289–308.
17.
ChangACWernovskyGWesselDL. Surgical management of late right ventricular failure after Mustard or Senning repair. Circulation. 1992;86(5 suppl):II140–II149.
18.
CochraneADKarlTRMeeRB.Staged conversion to arterial switch for late failure of the systemic right ventricle. Ann Thorac Surg. 1993;56(4):854–861; discussion861–862.
19.
SarkarDBullCYatesR. Comparison of long-term outcomes of atrial repair of simple transposition with implications for a late arterial switch strategy. Circulation. 1999;100(19 suppl):II176–II181.
20.
CettaFBonillaJJLichtenbergRCStasiorCTromanJEDeleonSY.Anatomic correction of dextrotransposition of the great arteries in a 36-year-old patient. Mayo Clin Proc. 1997;72(3):245–247.
21.
PadalinoMAStellinGBrawnWJ. Arterial switch operation after left ventricular retraining in the adult. Ann Thorac Surg. 2000;70(5):1753–1757.
22.
PoirierNCMeeRB.Left ventricular reconditioning and anatomical correction for systemic right ventricular dysfunction. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2000;3:198–215.
23.
DriscollDJOffordKPFeldtRHSchaffHVPugaFJDanielsonGK.Five- to fifteen-year follow-up after Fontan operation. Circulation. 1992;85(2):469–496.
24.
GewilligMWyseRKde LevalMRDeanfieldJE.Early and late arrhythmias after the Fontan operation: predisposing factors and clinical consequences. Br Heart J. 1992;67(1):72–79.
25.
Cromme-DijkhuisAHHessJHahlenK. Specific sequelae after Fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders. J Thorac Cardiovasc Surg. 1993;106(6):1126–1132.
26.
MertensLHaglerDJSauerUSomervilleJGewilligM.Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg. 1998;115(5):1063–1073.
27.
GentlesTLMayerJEGauvreauK. Fontan operation in five hundred consecutive patients: factors influencing early and late outcome. J Thorac Cardiovasc Surg. 1997;114(3):376–391.
28.
BolgerAPSharmaRLiW. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002;106(1):92–99.
29.
The SOLVD Investigators. Studies of left ventricular dysfunction: effect of enalapril on survival in patients with reduced ventricular ejection fractions and congestive heart failure. NEJM. 1991;325:293–302.
30.
PackerMPoole-WatsonPAArmstrongPW. Comparative effects of low and high doses of ACE inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312–2318.
31.
SwedbergKHeldPKjekhusJRasmussenKRydénLWedelH.Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II. NEJM. 1992;327(10):678–684.
32.
PittBMartinezFAMeurersGG. Randomized trial of losartan vs. captopril in patients > 65 with heart failure (Evaluation of Losartan in the Elderly). Lancet. 1997;349(9054):747–752.
33.
RieggerGAJBouzoHPetrP. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation. 1999;100(22):2224–2230.
34.
PittBZannadFRemmeWJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEJM. 1999;341(10):709–717.
35.
DavidKLNappiJM.The cardiovascular effects of eplerenone, a selective aldosterone receptor antagonist. Clin Ther. 2003;25(11):2647–2668.
36.
CIBIS-II Investigators and Committees. The cardiac insufficiency study II (CIBIS): a randomized trial. Lancet. 1999;353:9–13.
37.
HjalmarsonAGoldsteinSFagerbergB. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention in congestive heart failure. MERIT-HF Study Group. JAMA. 2000;283(10):1295–1302.
38.
FowlerMB.Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure. Am J Cardiol. 2004;93(9A):35B–39B.
39.
CaliffRMAdamsKFMcKennaWJ.A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44–54.
40.
ReinhartzOCopelandJGFarrarDJ.Thoratec ventricular assist devices in children with less than 1.3 m2 of body surface area. ASAIO J. 2003;49(6):727–730.
41.
SadeghiAMMarelliDTalamoMFazioDLaksH.Short-term bridge to transplant using the BVS 5000 in a 22-kg child. Ann Thorac Surg. 2000;70(6):2151–2153.
42.
PetrofskiJAHoopesCWBashoreTMRussellSDMilanoCA.Mechanical ventricular support lowers pulmonary vascular resistance in a patient with congenital heart disease. Ann Thorac Surg. 2003;75(3):1005–1007.
43.
MerkleFBoettcherWStillerBHetzerR.Pulsatile mechanical cardiac assistance in pediatric patients with the Berlin heart ventricular assist device. J Extra Corpor Technol. 2003;35(2):115–120.
44.
SpezialiGDriscollDJDanielsonGK. Cardiac transplantation for end-stage congenital heart defects: the Mayo Clinic experience. Mayo Cardiothoracic Transplant Team. Mayo Clin Proc. 1998;73(10):923–928.
45.
PigulaFAGandhiSKRistichJ. Cardiopulmonary transplantation for congenital heart disease in the adult. J Heart Lung Transplant. 2001;20(3):297–303.
46.
AbarbanellGLGoldbergCSDevaneyEJOhyeRGBoveELCharpieJR.Early surgical morbidity and mortality in adults with congenital heart disease: the University of Michigan experience. Congenit Heart Dis. 2008;3(2):82–89.
47.
MottARFraserCDJrMcKenzieED. Perioperative care of the adult with congenital heart disease in a free-standing tertiary pediatric facility. Pediatr Cardiol. 2002;23(6):624–630.
48.
CecchinFJohnsrudeCLPerryJCFriedmanRA.Effect of age and surgical technique on symptomatic arrhythmias after the Fontan procedure. Am J Cardiol. 1995;76(5):386–391.
49.
WeberHSHellenbrandWEKleinmanCSPerlmutterRARosenfeldLE.Predictors of rhythm disturbances and subsequent morbidity after the Fontan operation. Am J Cardiol. 1989;64(12):762–767.
50.
GelattMHamiltonRMMcCrindleBW. Risk factors for atrial tachyarrhythmias after the Fontan operation. J Am Coll Cardiol. 1994;24(7):1735–1741.
51.
NürnbergJHOvroutskiSAlexi-MeskishviliVEwertPHetzerRLangePE.New onset arrhythmias after the extracardiac conduit Fontan operation compared with the intraatrial lateral tunnel procedure: early and midterm results. Ann Thorac Surg. 2004;78(6):1979–1988.
52.
GiannicoSHammadFAmodeoA. Clinical outcome of 193 extracardiac Fontan patients: the first 15 years. J Am Coll Cardiol. 2006;47(10):2065–2073.
53.
BlaufoxADSleeperLABradleyDJPediatric Heart Network Investigators. Functional status, heart rate, and rhythm abnormalities in 521 Fontan patients 6 to 18 years of age. J Thorac Cardiovasc Surg. 2008;136(1):100–107.
54.
StephensonEALuMBerulCIPediatric Heart Network Investigators. Arrhythmias in a contemporary fontan cohort: prevalence and clinical associations in a multicenter cross-sectional study. J Am Coll Cardiol. 2010;56(11):890–896.
55.
BartzPJDriscollDJDearaniJA. Early and late results of the modified fontan operation for heterotaxy syndrome 30 years of experience in 142 patients. J Am Coll Cardiol. 2006;48(11):2301–2305.
56.
NakazawaMShinoharaTSasakiAStudy Group for Arrhythmias Long-Term After Surgery for Congenital Heart Disease: ALTAS-CHD study. Arrhythmias late after repair of tetralogy of fallot: a Japanese Multicenter Study. Circ J. 2004; 68(2):126–130. Erratum in: Circ J. 2004;68(4):403
57.
GatzoulisMABalajiSWebberSA. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356(9234):975–981.
58.
HarrisonDASiuSCHussainFMacLoghlinCJWebbGDHarrisL.Sustained atrial arrhythmias in adults late after repair of tetralogy of fallot. Am J Cardiol. 2001;87(5):584–588.
59.
Roos-HesselinkJPerlrothMGMcGhieJSpitaelsS.Atrial arrhythmias in adults after repair of tetralogy of Fallot. Correlations with clinical, exercise, and echocardiographic findings. Circulation. 1995;91(8):2214–2219.
60.
KobayashiJKawashimaYMatsudaH. Prevalence and risk factors of tricuspid regurgitation after correction of tetralogy of Fallot. J Thorac Cardiovasc Surg. 1991;102(4):611–616.
61.
MahleWTParksWJFyfeDASalleeD.Tricuspid regurgitation in patients with repaired tetralogy of Fallot and its relation to right ventricular dilatation. Am J Cardiol. 2003;92(5):643–645.
62.
MavroudisCBackerCLDealBJJohnsrudeCStrasburgerJ.Total cavopulmonary conversion and maze procedure for patients with failure of the Fontan operation. J Thorac Cardiovasc Surg. 2001;122(5):863–871.
63.
PerryJCFenrichALHulseJETriedmanJKFriedmanRALambertiJJ.Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol. 1996;27(5):1246–1250.
64.
SaulJPScottWABrownSIntravenous Amiodarone Pediatric Investigators. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation. 2005;112(22):3470–3477.
65.
TusethVJaatunHJDicksteinK.Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment. Heart. 2005;91(7):964–965.
66.
HoyerAWBalajiS.The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin Electrophysiol. 2007;30(8):1003–1008.
67.
RaoSOBoramanandNKBurtonDAPerryJC.Atrial tachycardias in young adults and adolescents with congenital heart disease: conversion using single dose oral sotalol. Int J Cardiol. 2009;136(3):253–257.
